BR0014524A - Subunit-optimized fusion proteins - Google Patents
Subunit-optimized fusion proteinsInfo
- Publication number
- BR0014524A BR0014524A BR0014524-6A BR0014524A BR0014524A BR 0014524 A BR0014524 A BR 0014524A BR 0014524 A BR0014524 A BR 0014524A BR 0014524 A BR0014524 A BR 0014524A
- Authority
- BR
- Brazil
- Prior art keywords
- fusion proteins
- subunit
- optimized fusion
- optimized
- fusion protein
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2434—Glucanases acting on beta-1,4-glucosidic bonds
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Abstract
Patente de Invenção: "PROTEìNAS DE FUSãO OTIMIZADAS COM SUBUNIDADE". Um método para a fabricação de uma proteína de fusão tendo: um primeiro membro fundido a um segundo membro onde os primeiro e segundo membros são escolhidos de modo que a proteína de fusão se agrupe em um complexo tendo um número de subunidades que otimiza a atividade da forma multimérica do segundo membro.Invention Patent: "SUBUNITY-OPTIMIZED FUSION PROTEINS". A method for making a fusion protein having: a first member fused to a second member where the first and second members are chosen so that the fusion protein is grouped into a complex having a number of subunits that optimizes the activity of the multimedia form of the second member.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39907999A | 1999-09-17 | 1999-09-17 | |
PCT/US2000/025558 WO2001019842A1 (en) | 1999-09-17 | 2000-09-18 | Subunit optimized fusion proteins |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0014524A true BR0014524A (en) | 2002-06-11 |
Family
ID=23578058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0014524-6A BR0014524A (en) | 1999-09-17 | 2000-09-18 | Subunit-optimized fusion proteins |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1237900A4 (en) |
JP (1) | JP2003509038A (en) |
KR (1) | KR20020039346A (en) |
CN (1) | CN1379782A (en) |
AU (1) | AU781462B2 (en) |
BR (1) | BR0014524A (en) |
CA (1) | CA2384766A1 (en) |
HU (1) | HUP0202702A2 (en) |
IL (1) | IL148549A0 (en) |
MX (1) | MXPA02002768A (en) |
NO (1) | NO20021244L (en) |
NZ (1) | NZ517774A (en) |
RU (1) | RU2002110116A (en) |
WO (1) | WO2001019842A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
EP1578917A4 (en) | 2001-07-19 | 2008-01-23 | Perlan Therapeutics Inc | Multimeric proteins and methods of making and using same |
KR102173260B1 (en) * | 2013-11-19 | 2020-11-03 | 리제너론 파마슈티칼스 인코포레이티드 | Non-human animals having a humanized b-cell activating factor gene |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111748A0 (en) * | 1993-12-03 | 1995-01-24 | Zeneca Ltd | Proteins |
GB9406974D0 (en) * | 1994-04-08 | 1994-06-01 | Pharmaceutical Proteins Ltd | Transgenic production |
US5959171A (en) * | 1994-08-17 | 1999-09-28 | Pharming B.V. | Method for the production of biologically active polypeptides in a mammal's |
US5635363A (en) * | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
JP2001512976A (en) * | 1997-02-25 | 2001-08-28 | ジェンザイム・トランスジェニックス・コーポレーション | Non-secretory protein produced by transgenic |
GB9708918D0 (en) * | 1997-05-01 | 1997-06-25 | Ppl Therapeutics Scotland Ltd | Methods |
US6548653B1 (en) * | 1998-06-15 | 2003-04-15 | Genzyme Transgenics Corporation | Erythropoietin analog-human serum albumin fusion |
-
2000
- 2000-09-18 BR BR0014524-6A patent/BR0014524A/en not_active IP Right Cessation
- 2000-09-18 IL IL14854900A patent/IL148549A0/en unknown
- 2000-09-18 HU HU0202702A patent/HUP0202702A2/en unknown
- 2000-09-18 CN CN00814422A patent/CN1379782A/en active Pending
- 2000-09-18 JP JP2001523619A patent/JP2003509038A/en active Pending
- 2000-09-18 AU AU38831/01A patent/AU781462B2/en not_active Ceased
- 2000-09-18 CA CA002384766A patent/CA2384766A1/en not_active Abandoned
- 2000-09-18 KR KR1020027003537A patent/KR20020039346A/en not_active Application Discontinuation
- 2000-09-18 NZ NZ517774A patent/NZ517774A/en unknown
- 2000-09-18 RU RU2002110116/13A patent/RU2002110116A/en unknown
- 2000-09-18 EP EP00963585A patent/EP1237900A4/en not_active Withdrawn
- 2000-09-18 WO PCT/US2000/025558 patent/WO2001019842A1/en not_active Application Discontinuation
- 2000-09-18 MX MXPA02002768A patent/MXPA02002768A/en unknown
-
2002
- 2002-03-13 NO NO20021244A patent/NO20021244L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA02002768A (en) | 2002-08-30 |
HUP0202702A2 (en) | 2002-12-28 |
CN1379782A (en) | 2002-11-13 |
WO2001019842A9 (en) | 2002-11-14 |
WO2001019842A1 (en) | 2001-03-22 |
JP2003509038A (en) | 2003-03-11 |
EP1237900A4 (en) | 2005-08-03 |
AU3883101A (en) | 2001-04-17 |
EP1237900A1 (en) | 2002-09-11 |
NO20021244D0 (en) | 2002-03-13 |
AU781462B2 (en) | 2005-05-26 |
IL148549A0 (en) | 2002-09-12 |
RU2002110116A (en) | 2004-03-10 |
CA2384766A1 (en) | 2001-03-22 |
NO20021244L (en) | 2002-05-13 |
KR20020039346A (en) | 2002-05-25 |
NZ517774A (en) | 2005-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE339507T1 (en) | ERYTHROPOIETIN ANALOG HUMAN SERUM-ALBUMIN FUSION PROTEIN | |
BR0208207A (en) | Reduction of fusion protein immunogenicity | |
CY1118991T1 (en) | PHARMACEUTICAL FORM OF HUMAN ANTIBODIES FOR TREATMENT OF TNF-ALPHA DISORDERS | |
CO4810339A1 (en) | NEW ARTIFICIAL STRUCTURES OF FUSION PROTEINS AND PREPARATION METHOD | |
EE03424B1 (en) | Method for the preparation of an allergy protein hydrolyzate formulation | |
PT1151004E (en) | A PROCESS FOR THE PREPARATION OF IL-1RA A THERAPEUTICALLY ACTIVE PROTEIN FROM CORPORATE FLUIDS | |
NO994757D0 (en) | Procedure for Oral Administration of Proteins | |
PT1032555E (en) | USED CYCLIC AMINO ACIDS AND DERIVATIVES AS PHARMACEUTICAL AGENTS | |
DE60139262D1 (en) | SYSTEM FOR RECONSTRUCTING JOINT SURFACES OF MAMMALS | |
DE69007975T2 (en) | FUSION PROTEIN CONSISTING OF GM-CSF AND IL-3. | |
DE240975T1 (en) | HUMAN GAMMA INTERFERON-SPECIFIC RECEPTOR PROTEIN, ANTIBODIES AGAINST THIS PROTEIN, METHOD FOR THE PRODUCTION OF THIS PROTEIN AND THIS ANTIBODY AND THIS PROTEIN AND THIS ANTIBODY CONTAINING. | |
KR890007750A (en) | DNA clone of human tissue factor inhibitor | |
BR9814760A (en) | Anti-freeze protein, nucleic acid sequence, and food product. | |
DE69434413D1 (en) | FUSION PROTEINS BETWEEN ANTIGENIC AMINO ACID SEQUENCES AND BETA - 2-MICROGLOBULIN | |
BR9509172A (en) | Native complement pathway protein DNA sequence construction of conjugated dna use of a process protein to reduce complement pathway protein in a mammal and pharmaceutical formulation | |
DK1244472T3 (en) | Particulate vitamin composition | |
BR0014524A (en) | Subunit-optimized fusion proteins | |
ES2117272T3 (en) | ORAL PHARMACEUTICAL COMPOSITIONS INCLUDING A PROTEIN OR PEPTIDE, AN ANTIBODY AND POLYMERIC SPHERES. | |
ATE309370T1 (en) | RETINOID METABOLIZING PROTEIN | |
DE69823225D1 (en) | FUSION PROTEINS, CONSISTING OF PROTEIN INHIBITORS | |
SE8502540L (en) | STABLE DENTALS CONTAINING DEXTRANAS | |
FI960308A0 (en) | Method for expression and purification of Haemophilus influenzae, type b P2 proteins | |
AU2486900A (en) | Rubredoxin fusion proteins, protein expression system and methods | |
DE69133166T2 (en) | INHIBITORS OF CATALYTIC ANTIBODIES | |
FI953422A0 (en) | Expression systems utilizing autolysing fusion proteins and novel reducing polypeptide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Free format text: GTC BIOTHERAPEUTICS, INC. (US) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES. |
|
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008 POR TER SIDO INDEVIDO. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A, 8A E 9A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009. |